Nancy Ryan Gray insider trades: Ligand Pharmaceuticals (LGND) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nancy reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | LGND | ↓ Sell | 6,571 | $205.45 | $1.4M | Direct | Nov 12, 2025 (5d) |
| May 9, 2024 | LGND | ↓ Sell | 934 | $83.20 | $78K | Direct | May 17, 2024 (8d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LGND insiders
Open-market trades in the last 12 months
About Nancy Ryan Gray's insider trades
Nancy Ryan Gray is a director at Ligand Pharmaceuticals (LGND). Since May 9, 2024, Nancy has reported no open-market purchases and 2 sales worth $1.4M on SEC Form 4. In the last 12 months: 1 sale ($1.4M).
Their filings also include grants and awards (11 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LGND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.